# Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

> **NCT03091400** · PHASE2 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 11 (actual)

## Conditions studied

- Memory Disorders
- Multiple Sclerosis

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03091400
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-16
- **Primary completion:** 2018-06-11
- **Final completion:** 2018-06-11
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091400, "Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT03091400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*